Leerink Partnrs Has Optimistic Outlook of TWST Q1 Earnings

Twist Bioscience Co. (NASDAQ:TWST - Free Report) - Analysts at Leerink Partnrs increased their Q1 2025 earnings estimates for shares of Twist Bioscience in a research note issued to investors on Monday, November 18th. Leerink Partnrs analyst P. Souda now forecasts that the company will post earnings of ($0.65) per share for the quarter, up from their prior estimate of ($0.71). The consensus estimate for Twist Bioscience's current full-year earnings is ($2.56) per share. Leerink Partnrs also issued estimates for Twist Bioscience's Q2 2025 earnings at ($0.62) EPS, Q3 2025 earnings at ($0.56) EPS, Q4 2025 earnings at ($0.51) EPS, FY2025 earnings at ($2.34) EPS and FY2026 earnings at ($1.84) EPS.

A number of other brokerages have also issued reports on TWST. Evercore ISI raised their price target on Twist Bioscience from $52.00 to $56.00 and gave the stock an "outperform" rating in a research note on Tuesday, October 1st. Leerink Partners upped their price target on shares of Twist Bioscience from $45.00 to $48.00 and gave the stock a "market perform" rating in a report on Thursday, October 17th. JPMorgan Chase & Co. raised their price target on shares of Twist Bioscience from $28.00 to $35.00 and gave the stock an "underweight" rating in a research note on Monday, August 5th. Scotiabank raised their price target on shares of Twist Bioscience from $50.00 to $54.00 and gave the stock a "sector outperform" rating in a research note on Tuesday. Finally, Robert W. Baird raised their price target on shares of Twist Bioscience from $46.00 to $48.00 and gave the stock an "outperform" rating in a research note on Tuesday. One investment analyst has rated the stock with a sell rating, one has given a hold rating and seven have given a buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $51.78.

Twist Bioscience Price Performance

Shares of NASDAQ TWST opened at $41.11 on Thursday. Twist Bioscience has a 1 year low of $23.07 and a 1 year high of $60.90. The firm has a 50-day simple moving average of $43.93 and a two-hundred day simple moving average of $46.15. The company has a market cap of $2.44 billion, a P/E ratio of -11.42 and a beta of 1.78.

Institutional Trading of Twist Bioscience

A number of institutional investors have recently bought and sold shares of the stock. American International Group Inc. boosted its stake in Twist Bioscience by 0.8% in the 1st quarter. American International Group Inc. now owns 28,506 shares of the company's stock worth $978,000 after purchasing an additional 213 shares in the last quarter. Caprock Group LLC boosted its stake in Twist Bioscience by 2.9% in the 2nd quarter. Caprock Group LLC now owns 7,851 shares of the company's stock worth $387,000 after purchasing an additional 220 shares in the last quarter. Signaturefd LLC boosted its stake in Twist Bioscience by 63.0% in the 3rd quarter. Signaturefd LLC now owns 792 shares of the company's stock worth $36,000 after purchasing an additional 306 shares in the last quarter. Arizona State Retirement System raised its position in Twist Bioscience by 1.9% during the 2nd quarter. Arizona State Retirement System now owns 16,187 shares of the company's stock worth $798,000 after buying an additional 308 shares during the last quarter. Finally, Massachusetts Financial Services Co. MA raised its position in Twist Bioscience by 3.5% during the 2nd quarter. Massachusetts Financial Services Co. MA now owns 9,279 shares of the company's stock worth $457,000 after buying an additional 312 shares during the last quarter.

Insider Activity

In other news, CAO Robert F. Werner sold 1,448 shares of the firm's stock in a transaction dated Wednesday, November 6th. The shares were sold at an average price of $44.60, for a total value of $64,580.80. Following the sale, the chief accounting officer now directly owns 45,620 shares in the company, valued at approximately $2,034,652. This trade represents a 3.08 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Emily M. Leproust sold 14,334 shares of the firm's stock in a transaction dated Wednesday, November 6th. The shares were sold at an average price of $44.60, for a total transaction of $639,296.40. Following the completion of the sale, the chief executive officer now owns 589,552 shares in the company, valued at $26,294,019.20. This represents a 2.37 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 98,118 shares of company stock worth $4,391,151. Corporate insiders own 3.92% of the company's stock.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.